|
![]() |
|
|
Sonata: profile and news
Perlman is a delight at Pabst 16 May 2006 Cooper ramps up the amperage, makes it work 16 May 2006 Emory Chamber Music Society of Atlanta’s 2006-2007 Season ... 16 May 2006 Taliban escapees caught in Bulgaria, Central Asia 16 May 2006 Hinton Center grant to train apprentice carpenters 16 May 2006 Deborah Voigt and Renée Fleming vs. the Ghosts of Met Divas Past 16 May 2006 Auction of blocks with building entitlements 16 May 2006 Dozier: And a happy birthday to ... 16 May 2006 First Korean celebrity with Madame Tussauds wax statue 16 May 2006 AutoPacific Announces 2006 Vehicle Satisfaction Awards 16 May 2006 Maxim Vengerov, Barbican Hall, London May 15, 2006 Hyundai Sonata May 1, 2006 Titan eyes youth via Sonata May 3, 2006 Sonata, India’s largest watch brand signs Mahendra Singh Dhoni ... Apr 26, 2006 Dhoni to endorse Sonata watches Apr 26, 2006 Dhoni to endorse Sonata watches Apr 25, 2006 Hyundai Sonata Apr 17, 2006 Sonata Soft, Subros, VIP Inds & Visakha Inds Q4 Results Apr 25, 2006 Sonata Software Q4 net loss at Rs 8.4cr Apr 25, 2006 Sonata signs up Dhoni as brand amabassador Apr 25, 2006 India : Dhoni to arm his wrist with Sonata Apr 26, 2006 Sobre Ruedas Magazine Names Hyundai Sonata 'Best Sedan 2005 Award ... Apr 29, 2006 Hyundai Sonata Tunefully Raises The Tone Apr 26, 2006 Sonata Final dividend 60%. Total Dividend at 100%, maintains at 54 ... Apr 26, 2006 Violinist catches fire at festival May 16, 2006 Concert Review: Camerata ends season with exuberance May 15, 2006 Indonesian man jailed for plotting act of terrorism May 15, 2006 Sonata packs more grunt with less thirst Apr 20, 2006 A Most Unusual Mozart Collaboration May 14, 2006 Pianist Fliter makes spectacular debut with Chopin May 16, 2006 Listings: This week, don't miss... May 13, 2006 Church members have busy week May 15, 2006 Chopin and Liszt meet their match in Pollini May 15, 2006 ASO plays to full house on Mother's Day May 15, 2006 Mahendra Singh Dhoni to endorse Sonata Apr 25, 2006 Music : Heber Springs keys up for chamber music festival May 12, 2006 Mahendra Singh Dhoni to bat for Sonata Apr 25, 2006 Mitsuko Uchida Performs Mozart May 12, 2006 Imogen Cooper at Zankel Hall: Virtuosity Without Razzle-Dazzle May 10, 2006 Entourage is big, noisy May 15, 2006 Music: On the crest of a wave May 13, 2006 'Emerging Avant-Pop': From Charles Ives to Frank Zappa May 10, 2006 Other information Indication For the treatment of short-term treatment of insomnia in adults Pharmacology Zaleplon is a nonbenzodiazepine hypnotic from the pyrazolopyrimidine class and is indicated for the short-term treatment of insomnia. While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABABZ) receptor complex. Subunit modulation of the GABABZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models. Zaleplon binds selectively to the brain alpha subunit of the GABA A omega-1 receptor. Mechanism Of Action Zaleplon exerts its action through subunit modulation of the GABABZ receptor chloride channel macromolecular complex.Zaleplon binds selectively to the brain alomega-1 receptor situated on the alpha subunit of the GABA-A/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding. Drug Category Hypnotics and Sedatives; Anticonvulsants; Anxiolytics sedatives and hypnotics; ATC:N05CF03 Brand Names/Synonyms CHEMBANK1807; Dea No. 2781; L846; Sonata; ZAL 846; Zalaplon; Zaleplon; Zaleplon [Usan:Inn] Dosage Forms CAPSULE Absorption Absorption Zaleplon is rapidly and almost completely absorbed following oral administration. Interactions -->Interactions for Zaleplon: As with all drugs, the potential exists for interaction with other drugs by a variety of mechanisms. CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration. The potentiation resulted from a CNS pharmacodynamic interaction; zaleplon did not affect the pharmacokinetics of ethanol. Imipramine: Coadministration of single doses of Sonata 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug. Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance. Additionally, paroxetine did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in zaleplonís metabolism. Thioridazine: Coadministration of single doses of Sonata 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration. The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug. Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine. In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER. Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve. However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated. Caution should be exercised when these 2 agents are coadministered. Drugs That Induce CYP3A4 Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon. Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%. The coadministration of a potent CYP3A4 enzyme inducer, although not posing a safety concern, thus could lead to ineffectiveness of zaleplon. An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital. Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose. Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplon's maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve. The magnitude of interaction with multiple doses of erythromycin is unknown. Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon. A routine dosage adjustment of zaleplon is not considered necessary. Drugs That Inhibit Aldehyde Oxidase The aldehyde oxidase enzyme system is less well studied than the cytochrome P450 enzyme system. Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known. There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug. However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible. Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism. Concomitant administration of Sonata (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon. An initial dose of 5 mg should be given to patients who are concomitantly being treated with cimetidine. Drugs Highly Bound to Plasma Protein Zaleplon is not highly bound to plasma proteins (fraction bound 60%±15%); therefore, the disposition of zaleplon is not expected to be sensitive to alterations in protein binding. In addition, administration of Sonata to a patient taking another drug that is highly protein bound should not cause transient increase in free concentrations of the other drug. Drugs with a Narrow Therapeutic Index Digoxin: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days). Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin. Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs. There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug. This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose. Chemical IUPAC Name N-[3-(9-cyano-2,6,7-triazabicyclo[4.3.0]nona-2,4,7,9-tetraen-5-yl)phenyl]-N-ethyl-ethanamide Chemical Formula C17H15N5O Half Life ~1 hour Drug Type Approved Drug # Accession No APRD00411 CAS Registry Number 151319-34-5 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |